Pfizer reports positive Phase 3 results for Elrexfio in relapsed multiple myeloma

Pfizer announced that its antibody-drug conjugate Elrexfio achieved a statistically significant and clinically meaningful improvement in progression-free survival for patients with relapsed or refractory multiple myeloma in a Phase 3 trial.

The trial enrolled patients whose disease had progressed after prior therapies, and the data showed a clear benefit compared with standard of care, meeting the study's primary endpoint.

The results position Elrexfio as a potential new option for this hard-to-treat population, though further regulatory review will be required before commercial launch.

In a separate note, market data firm ICON was reported to have overstated its revenue figures, a reminder of ongoing scrutiny of financial reporting in the sector.